The pathophysiology is unclear, but risk factors are thought to be the same as the type 1 diabetic patients who rapidly improved A1c in the Diabetes Control and Complications Trial: long duration of diabetes mellitus, long duration of poor glycemic control, worse baseline level of DR prior to treatment and magnitude of reduction in A1c after treatment
In assessing the CGI-I, one subject scored a 4 (no change/improvement), four subjects scored a 3 (minimally improved), and one subject scored a 6 (much worse)
FOXO4-DRI is a synthetic D-retro-inverso peptide studied as a senolytic, meaning it is designed to selectively clear senescent cells
10.1089/jop.2010.0123 53 GutierresV
If itching is severe or occurs alongside hives or swelling, notify your prescriber immediately
Patients typically report increased mental clarity, reduced fatigue, and a sense of physical lightness early in the protocol